- Home
- PEPG vs ATNM Comparison
PEPG vs ATNM Comparison
Compare PEPG & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- ATNM
- Stock Information
- Founded
- PEPG 2018
- ATNM 2000
- Country
- PEPG United States
- ATNM United States
- Employees
- PEPG N/A
- ATNM N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- PEPG Health Care
- ATNM Health Care
- Exchange
- PEPG Nasdaq
- ATNM Nasdaq
- Market Cap
- PEPG 52.4M
- ATNM 51.5M
- IPO Year
- PEPG 2022
- ATNM N/A
- Fundamental
- Price
- PEPG $1.42
- ATNM $1.69
- Analyst Decision
- PEPG Buy
- ATNM Strong Buy
- Analyst Count
- PEPG 3
- ATNM 3
- Target Price
- PEPG $7.67
- ATNM $4.67
- AVG Volume (30 Days)
- PEPG 216.6K
- ATNM 213.3K
- Earning Date
- PEPG 05-08-2025
- ATNM 08-04-2025
- Dividend Yield
- PEPG N/A
- ATNM N/A
- EPS Growth
- PEPG N/A
- ATNM N/A
- EPS
- PEPG N/A
- ATNM N/A
- Revenue
- PEPG N/A
- ATNM N/A
- Revenue This Year
- PEPG N/A
- ATNM N/A
- Revenue Next Year
- PEPG N/A
- ATNM N/A
- P/E Ratio
- PEPG N/A
- ATNM N/A
- Revenue Growth
- PEPG N/A
- ATNM N/A
- 52 Week Low
- PEPG $0.88
- ATNM $1.03
- 52 Week High
- PEPG $19.30
- ATNM $8.64
- Technical
- Relative Strength Index (RSI)
- PEPG 46.62
- ATNM 57.91
- Support Level
- PEPG $1.35
- ATNM $1.51
- Resistance Level
- PEPG $1.55
- ATNM $1.69
- Average True Range (ATR)
- PEPG 0.15
- ATNM 0.11
- MACD
- PEPG -0.00
- ATNM -0.00
- Stochastic Oscillator
- PEPG 18.42
- ATNM 56.72
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.